Analysts See $-0.76 EPS for Summit Therapeutics plc (SMMT) on June, 13

May 17, 2018 - By Irene Marshall

Summit Therapeutics plc (NASDAQ:SMMT) Corporate Logo

Investors wait Summit Therapeutics plc (NASDAQ:SMMT)’s quarterly earnings on June, 13., according to Zacks. Last year’s earnings per share was $-0.5, while now analysts expect change of 52.00 % down from current $-0.76 earnings per share. Wall Street now forecasts -33.91 % EPS growth despite Summit Therapeutics plc last quarter’s EPS of $-1.15. SMMT touched $13.95 during the last trading session after $0.25 change.Summit Therapeutics plc is uptrending after having risen 4.52% since May 17, 2017. SMMT has 79,366 volume or 105.88% up from normal. SMMT underperformed by 7.03% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

A total of 8 analysts rate Summit Therapeutics plc – American Depositary Shares (NASDAQ:SMMT) as follows: 8 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:SMMT) has 10 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, April 11 the stock has “Buy” rating by Canaccord Genuity. On Friday, April 13 the firm has “Buy” rating by SunTrust given. On Tuesday, March 6 the rating was maintained by Canaccord Genuity with “Buy”. The company rating was reinitiated by H.C. Wainwright on Friday, December 1. On Friday, January 26 the rating was maintained by Oppenheimer with “Outperform”.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America.The firm is worth $218.72 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).Currently it has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

For more Summit Therapeutics plc (NASDAQ:SMMT) news released briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Summit Therapeutics plc : Total voting rights” released on May 01, 2018, “Award of Share Options and Restricted Stock Units” on April 23, 2018, “Summit Therapeutics plc : Notice of AGM” with a publish date: May 03, 2018, “Summit Therapeutics (SMMT) Announces New 24-Week Analyses from PhaseOut DMD” and the last “Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late …” with publication date: April 23, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: